MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: January 3, 2007

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/713,149
Filing Date	11/17/2003
First Named Inventor	Robert H. GETZENBERG
Group Art Unit	1642
Examiner Name	Peter J. Reddig
Attorney Docket Number	076333-0331

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/PR/	A1	4,882,268		Penman et al.	11/21/89	
/PR/	A2	5,273,877		Fey et al.	12/28/93	
/PR/	A3	5,849,509		Coffey et al.	12/15/98	
/PR/	A4	5,866,535		Getzenberg et al.	2/2/99	
/PR/	A5	4,885,236		Penman et al.	12/5/89	
/PR/	A6	5,824,490		Coffey et al.	10/20/98	
/PR/	A7	5,547,928		Wu et al.	08/20/96	
/PR/	A8	6,232,443		Getzenberg	3/1998	
/PR/	A9	5,989,826		Beausang et al.	11/23/1999	
/PR/	A10	6,162,608		Beausang et al.	12/19/2000	
/PR/	A11	6,410,247		Beausang et al.	6/25/2002	
/PR/	A12	Re 35,747		Penman et al.	3/17/1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
/PR/	A13	WO	95/16919			6/22/95		
/PR/	A14	WO	93/09437			5/13/93		
/PR/	A15	WO	94/00573			1/6/94		
/PR/	A16	WO	87/03910			7/2/87		
/PR/	A17	WO	94/18222			8/18/94		
/PR/	A18	WO	97/16206			9/5/97		
/PR/								

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
/PR/	A19	Miyanaga, N. et al., "Nuclear Matrix Proteins as a Urine Marker for Transitional Cell Carcinoma of the Bladder", The Journal of Urology Supplement, Vol. 153, No. 4 (XP-002068914)	
/PR/	A20	Merrifield S. et al., "The Performance of the NMP22™ Test Kit: A Quantitative Enzyme Immuno-Assay for Bladder Cancer", Tumor Biology, 17 (suppl 1)(1996) (XP-002068915)	
/PR/	A21	Getzenberg, R. et al., "Bladder Cancer-associated Nuclear Matrix Proteins", Cancer Research Vol. 56, No. 7, pp. 1690-1694, (1996). (XP-002068894).	
/PR/	A22	Konety, B.R., Identification of Nuclear Matrix Protein Alterations Associated with Renal Cell Carcinoma", The Journal of Urology, Vol. 159, No. 4, pp. 1359-1363 (1998). (XP002068895).	

Examiner Signature	/Peter Reddig/	Date Considered	07/05/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: January 3, 2007

(use as many sheets as necessary)

Sheet | 2 | of | 4

Complete if Known	
Application Number	10/713,149
Filing Date	11/17/2003
First Named Inventor	Robert H. GETZENBERG
Group Art Unit	1642
Examiner Name	Peter J. Reddig
Attorney Docket Number	076333-0331

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
/PR/	A23	Eberharten A., et al., "Nuclear Matrix of the Lower Eukaryote Physarum Polycephalum and the mammalian epithelial LLC-PKI cell line—A comprehensive investigation of different preparation procedures", Vol. 212, No. 2, pp. 573-580 (1992). (XP02068893).	
/PR/	A24	Keesee, S.K., et al., "Utilization of Nuclear Matrix Proteins for Cancer Diagnosis", Critical Reviews in Eukaryotic Gene Expression", Vol., 6, No. 2&3, pp. 189-214 (1996). (XP002069158).	
/PR/	A25	Getzenberg, R.H., "Nuclear Matrix and the Regulation of Gene Expression: Tissue Specificity", Journal of Cellular Biochemistry, Vol. 55, pp. 22-31 (1994).	
/PR/	A26	Getzenberg, R.H. et al., "Identification of Nuclear Matrix Proteins in the Cancer and Normal Rat Prostate", Cancer Research, Vol. 51, pp. 6514-6520 (1994).	
/PR/	A27	Berezney, R. et al., "Identification of a Nuclear Protein Matrix", Biochemical and Biophysical Research Communications, Vol. 60, No. 4 (1974).	
/PR/	A28	Fey, E.G. et al., "The Nuclear Matrix: Defining Structural and Functional Roles", Eukaryotic Gene Expression, pp. 127-143 (1991).	
/PR/	A29	Fey E.G. et al., "Tumor promoters induce a specific morphological signature in the nuclear matrix-intermediate filament scaffold of Madin-Darby canine kidney (MDCK) cell colonies", Proc. Natl. Acad. Sci. USA, vol. 81, pp. 4409-4413 (1984),	
/PR/	A30	Fey E.G. et al., "Nuclear matrix proteins reflect cell type of origin in cultural human cells", Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 121-125 (1988).	
/PR/	A31	Fey E.G. et al., "Epithelial Cytoskeletal Framework and Nuclear Matrix-Intermediate Filament Scaffold: Three-dimensional Organization and Protein Composition", The Journal of Cell Biology, Vol. 98, pp. 1973-1984 (1984).	
/PR/	A32	Weidner, N. et al., "Rapid Communication, Localization of Nuclear Matrix Proteins (NMPs) in Multiple Tissue Types with NM-200.4™ (An Antibody Strongly Reactive with NMPs Found in Breast Carcinoma)", American Journal of Pathology, Vol. 138, No. 6, pp. 1293-1298 (1991).	
/PR/	A33	Huse, W.D. et al., "Generation of a Large Combinatorial Library of the Immunoglobuline Repertoire in Phage Lambda", Research Article, pp. 1275-1281 (1989).	
/PR/	A34	Mullinax, R.L. et al., "Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage λ immunoexpression library", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 8095-8099 (1990).	
/PR/	A35	Diener E. et al., Specific Immunosuppression by Immunotoxins Containing Daunomycin", Science Vol. 231, pp. 148-150 (1986).	
/PR/	A36	Greiner, J.W., "Recombinant Interferon Enhances Momoclonal Antibody –Targeting of Carcinoma Lesions in Vivo", Reports, pp. 895-898 (1987).	
/PR/	A37	Wolff B. et al., "The Use of Monoclonal Anti-Thy1IgG1 for the Targeting of Liposomes to AKR-A Cells in Vitro and In Vivo", Biochimica et Biophysica Acta, Vol. 802, pp. 259-273 (1984).	

Examiner Signature	/Peter Reddig/	Date Considered	07/05/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: January 3, 2007

(use as many sheets as necessary)

Sheet | 3 | of | 4

Complete if Known	
Application Number	10/713,149
Filing Date	11/17/2003
First Named Inventor	Robert H. GETZENBERG
Group Art Unit	1642
Examiner Name	Peter J. Reddig
Attorney Docket Number	076333-0331

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
/PR/	A38	Weintraub H.M. "Antisense RNA and DNA" Scientific American pp. 40-46 (1990).	
/PR/	A39	Cech, T.R. Ph.D., Ribozymes and Their Medical Implications", JAMA, Vol. 260, No. 20, pp. 3030-3034 (1988).	
/PR/	A40	Haseloff, J. et al. "Simple RNA enzymes with new and highly specific endoribonuclease activities" Nature, Vol. 334, pp. 585-591 (1988).	
/PR/	A41	Bejany, D.E. et al., "Malignant Vesical Tumors Following Spinal Cord Injury", The Journal of Urology, Vol. 138, pp. 1390-1392 (1987).	
/PR/	A42	Kaufman, J.M. et al. "Bladder Cancer and Squamous Metaplasia in Spinal Cord Injury Patients", pp. 967-971 (1977).	
/PR/	A43	Melzak J. M.D., "The Incidence of Bladder Cancer in Paraplegia", Paraplegia, pp. 85-96.	
/PR/	A44	Nyquist R.H., M.D. et al., "Mortality and Survival in Traumatic Myelof During Nineteen Years, from 1946 to 1965", Paraplegia, pp. 22-48.	
/PR/	A45	El-Masri, W.S., "Bladder Cancer After Spinal Cord Injury", International Medical Socieny of Paraplegia, pp. 265-270 (1981).	
/PR/	A46	Geisler, W.O., et al. "Survival in Traumatic Transverse Myelitis", Paraplegia, Vol. 14, pp. 262-275 (1977).	
/PR/	A47	Hackler R.H., "A 25-Year Prospective Mortality Study In the Spinal Cord Injured Patient: Comparison With the Long-Term Living Paraplegic", The Journal of Urology, Vol. 117, pp. 486-488 (1977).	
/PR/	A48	Pound, C.R. et al., "Differential Nuclear Matrix Protein (NMP) Patterns In Normal Renal Tissue and Renal Cell Carcinoma (RCC)", 92nd Annual Meeting of the American Urological Association, New Orleans, LA, USA, (1997) J. of Urol. Vol. 157 (4 suppl.) (1997) (XP-002076374).	
/PR/	A49	Konety B.R. et al., "Characteristic Nuclear Matrix Protein Alterations in Renal Cell Carcinoma (RCC)", 92ND Annual Meeting of the American Urological Association, New Orleans, LA, USA (1997), J. or Urol., Vol. 157 (4 suppl.) (1997) (XP-002076375).	
/PR/	A50	Gordon, J.N. et al., "Altered Extracellular Matrices Influence Cellular Processes and Nuclear Matrix Organizations of Overlying Human Bladder Urothelial Cells", Cancer Research, Vol. 53, pp. 4971-4977 (1993).	
/PR/	A51	Cupo, J., "Electrophoretic analysis of nuclear matrix proteins and the potential clinical applications", Elsevier Science Publishers B.V., pp. 389-406 (1991).	
/PR/	A52	Partin, A.W. et al., "Nuclear Matrix Protein Patterns in Human Benign Prostatic Hyperplasia and Prostate Cancer", Cancer Research, Vol. 53, pp. 744-746 (1993).	

Examiner Signature	/Peter Reddig/	Date Considered	07/05/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,149
				Filing Date	11/17/2003
Date Submitted: January 3, 2007				**First Named Inventor**	Robert H. GETZENBERG
				Group Art Unit	1642
(use as many sheets as necessary)				Examiner Name	Peter J. Reddig
Sheet	4	of	4	Attorney Docket Number	076333-0331

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
/PR/	A53	Russell, P.J. et al. "Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer", Cell biophysics, Vols. 24/25 pp. 155-61 (1994).	
/PR/	A54	Kingsley E.A. et al., "Characterization of the anti-bladder-cancer monoclonal antibody BLCA -8: identification of its antigen as a neutral glycolipid", Cancer Immunology, Immunotherapy, Vol. 41, No. 6, pp. 348-54 (1995) (XP000872998).	
/PR/	A55	Fradet Y., "Molecular and Immunologic approaches in the management of bladder cancer", Urologic Clinics of North America, Vol. 18. No. 3, pp. 515-24 (1991) (XP000881253).	
/PR/	A56	Replogle-Schwab R. et al., "The utilization of nuclear matrix proteins for cancer diagnosis", Critical Reviews in Eukaryotic Gene Expression, Vol. 6, Nos. 2-3, pp. 103-13 (1996), (XP000881255).	
/PR/	A57	Pirtskalaishvili G. et al., "Use of urine-based markers for detection and monitoring of bladder cancer", Techniques in Urology, Vol. 5, No. 4, pp. 179-84 (1999) (XP000881344).	
/PR/	A58	J.E. Celis et al, "Expression of the transformation-sensitive protein "cyclin" in normal human epidermal basel cells and simian virus 40-transformed keratinocytes," Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 3128-3132 (1984).	
/PR/	A59	J.E. Celis et al., "Intermediate filaments in monkey kidney TC7 cells: Focal centers and interrelationship with other cytoskeletal systems", Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 1117-1121 (1984).	
/PR/	A60	R.G. DiScipio et al., "Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9", Proc. Natl. Acad. Sci. USA, vol. 81, pp. 7298-7302 (1984).	
/PR/	A61	R.B. Merrifield, "Solid Phase Peptide Synthesis. I. The synthesis of a Tetrapeptide", J. Am. Chem. Soc., Vol. 85, No. 14, pp. 2149-2154 (1963).	
/PR/	A62	Stewart and Young, "Solid Phase Peptide Synthesis" Freeman Publ. 1969, pp. 27-61.	
/PR/	A63	J.Y. Douillard et al., "Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors", Hybridoma, Vol. 5, Suppl. 1 (1986) pp. S139-S149.	
/PR/	A64	R. Fraley et al., "New Generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", Trends Biochem. Sci., Vol. 6, pp. 77-80 (1981).	
/PR/	A65	T. Gura, Science, "Systems for Identifying New Drugs Are Often Faulty", Nov. 1997, Vol. 278, pp. 1041-1042.	
/PR/	A66	LH Hartwell et al., Science, "Integrating Genetic Approaches into the Discovery of Anticancer Drugs" Nov. 1997, Vol. 278, pp. 1064-1068.	

Examiner Signature	/Peter Reddig/	Date Considered	07/05/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.